Kamada (KMDA) Upgraded by Zacks Investment Research to “Hold”

Kamada (NASDAQ:KMDA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Friday.

According to Zacks, “Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. “

A number of other analysts have also recently commented on the company. ValuEngine upgraded Kamada from a “sell” rating to a “hold” rating in a research report on Thursday. HC Wainwright restated a “buy” rating on shares of Kamada in a research report on Thursday. Chardan Capital initiated coverage on Kamada in a research report on Friday, February 2nd. They issued a “buy” rating and a $7.00 price target on the stock. Finally, Jefferies Group restated a “buy” rating and issued a $7.00 price target on shares of Kamada in a research report on Thursday, October 12th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $7.00.

Shares of Kamada (NASDAQ:KMDA) opened at $5.00 on Friday. The company has a current ratio of 3.30, a quick ratio of 2.73 and a debt-to-equity ratio of 0.02. Kamada has a 52-week low of $3.75 and a 52-week high of $8.61. The company has a market capitalization of $193.26, a PE ratio of 29.41 and a beta of 1.14.

Kamada (NASDAQ:KMDA) last posted its earnings results on Wednesday, February 7th. The biotechnology company reported $0.16 EPS for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.10. Kamada had a return on equity of 9.06% and a net margin of 6.71%. The business had revenue of $35.71 million for the quarter, compared to analysts’ expectations of $32.90 million. research analysts forecast that Kamada will post 0.16 EPS for the current fiscal year.

A number of hedge funds have recently modified their holdings of KMDA. Jane Street Group LLC acquired a new position in Kamada during the 3rd quarter worth approximately $112,000. Worth Venture Partners LLC acquired a new position in Kamada during the 3rd quarter worth approximately $246,000. Navellier & Associates Inc acquired a new position in Kamada during the 2nd quarter worth approximately $303,000. Analyst IMS Investment Management Services Ltd. increased its position in Kamada by 125.5% during the 3rd quarter. Analyst IMS Investment Management Services Ltd. now owns 89,843 shares of the biotechnology company’s stock worth $431,000 after purchasing an additional 50,000 shares during the period. Finally, Vanguard Group Inc. increased its position in Kamada by 6.5% during the 2nd quarter. Vanguard Group Inc. now owns 468,390 shares of the biotechnology company’s stock worth $2,810,000 after purchasing an additional 28,382 shares during the period. Hedge funds and other institutional investors own 6.26% of the company’s stock.

WARNING: “Kamada (KMDA) Upgraded by Zacks Investment Research to “Hold”” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://sportsperspectives.com/2018/02/11/kamada-kmda-upgraded-by-zacks-investment-research-to-hold.html.

Kamada Company Profile

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.

Get a free copy of the Zacks research report on Kamada (KMDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply